Logo - springer
Slogan - springer

Biomedical Sciences - Human Genetics | Journal of Molecular Medicine - incl. option to publish open access (Societies)

Journal of Molecular Medicine

Journal of Molecular Medicine

Editors-in-Chief: D. Ganten; G.L. Semenza; Th. Sommer

ISSN: 0946-2716 (print version)
ISSN: 1432-1440 (electronic version)

Journal no. 109

$199.00 Personal Rate e-only for the Americas
Get Subscription

Online subscription, valid from January through December of current calendar year

Immediate access to this year's issues via SpringerLink

1 Volume(-s) with 12 issue(-s) per annual subscription

Automatic annual renewal

More information: >> FAQs // >> Policy

Editorial Team


Detlev Ganten, M.D., Ph.D.  

Charite, Berlin

Detlev Ganten
Detlev Ganten served as the Founding Director of the Max Delbrück Center for Molecular Medicine (MDC) Berlin Buch (1991 – 2004). From 2004 to 2008 Professor Ganten was the CEO of the Charité – Universitätsmedizin Berlin. He is now Chairman of the Board of the Charité Foundation, Chairman of the Board of Trustees of the Max Planck Institutes for Plant Physiology and Colloid Chemistry in Potsdam and President of the World Health Summit. He gave "J Mol Med" its international character as the successor journal to the prestigious, traditional German journal “Klinische Wochenschrift” (founded in 1864). He has made important scientific contributions in the area of hormonal regulation of blood pressure, the renin-angiotensin system, genomics and molecular genetics of cardiovascular diseases, pharmacology of antihypertensive drugs and evolutionary medicine. He has received the Cross of Merit of Germany and the rank of commander of the French Légion d’Honeur.

Gregg L. Semenza, M.D., Ph.D.  

Johns Hopkins University, Baltimore

Gregg L. Semenza
Gregg Semenza is currently the C. Michael Armstrong Professor at Johns Hopkins with appointments in Pediatrics, Medicine, Oncology, Radiation Oncology, Biological Chemistry, and Genetic Medicine and has served as founding Director of the Vascular Program in the Johns Hopkins Institute for Cell Engineering. His laboratory identified hypoxia-inducible factor 1 (HIF-1), a protein that allows metazoan cells to respond to changes in oxygen availability. The purification of HIF-1 in 1995 opened the field of oxygen biology to molecular analysis and has revealed major roles for HIF-1 in many evolutionary, developmental, physiological, and pathological processes. Dr. Semenza is a recipient of the 2010 Canada Gairdner International Award and the 2012 Grand Prix Lefoulon-Delalande.

Thomas Sommer, Ph.D.  

Max Delbrück Center for Molecular Medicine, Berlin

Thomas Sommer is currently Scientific Director of the Max Delbrück Center for Molecular Medicine in Berlin and is full professor for Cellular Biochemistry at Charité – Universitätsmedizin Berlin.
His laboratory made significant contributions to the role of the ubiquitin proteasome pathway in proteolysis in and at the endoplasmic reticulum.
The focus of his current research is directed at understanding the interplay of ubiquitin ligases and molecular chaperones in protein quality control pathways.

Editorial Office 

Phoebe Marković 

Phoebe Markovic
Phoebe Marković identified the AF-6 homologue Canoe as DRap1 effector mediating morphogenetic movements during Drosophila embryonic development in Ulrike Gaul´s lab at the Rockefeller University, NY, and obtained her PhD from the private University Witten-Herdecke, Germany. For postdoctoral research, she moved to the Max Delbück Center for Molecular Medicine to study neurodegeneration with Erich Wanker. In May 2010 she joined "J Mol Med" as Managing Editor.

Joo-Hee Wälzlein 

Joo-Hee Wälzlein received her PhD in cellular neuroscience at the Max Delbrück Center for Molecular Medicine in Berlin. She then completed several years of postdoctoral research at the King’s College and University College London. There she focused on prion research in John Collinge’s lab, where she worked in the field of drug discovery and establishment of a neurotoxicity assay. In September 2016 she took up the position of Managing Editor of “Journal of Molecular Medicine”.

Associate Editors 

Stephen Archer  

Queen’s University at Kingston, Kingston

Stephen Archer
Stephen Archer´s research interests focus on molecular mechanisms of O2 sensing and mitochondrial biology. His work has helped create the redox hypothesis of oxygen sensing, in which mitochondria serve as vascular oxygen sensors that, through production of reactive oxygen species, regulate potassium channels and thereby control vascular tone in response to changes in PO2. He also has a translational research program developing experimental therapeutics for pulmonary hypertension, patent ductus arteriosus and lung cancer.

Dan Arking  

Johns Hopkins University, Baltimore

Dan Arking
Dan Arking's research focuses on the genomics of complex human disease, with the primary goal of identifying and characterizing genetic variants that modify risk for human disease. His group has pioneered the use of genome-wide association studies (GWAS), which allow for an unbiased screen of virtually all common genetic variants in the genome. Dr. Arking is currently developing improved GWAS methodology, as well as exploring the integration of additional genome level data (RNA expression, DNA methylation, protein expression) to improve the power to identify genetic influences of disease. His lab is actively involved in researching autism, a childhood neuropsychiatric disorder, as well as cardiovascular genomics, with a focus on sudden cardiac death (SCD).

Michael Bader  

Max Delbrück Center for Molecular Medicine, Berlin

Michael Bader
Michael Bader’s research focuses on cardiovascular hormones, in particular on angiotensins, kinins, and serotonin. He has revealed numerous physiological functions of these hormones using genetically modified mouse and rat models. He has discovered TPH2, the enzyme generating serotonin in the brain and has thereby shown that there are two completely independent serotonin systems in vertebrates, one in the periphery and one in the CNS.

Sean Colgan 

University of Colorado, School of Medicine

Sean Colgan´s research aims at understanding innate immunity in at mucosal surfaces. His group has defined novel metabolic pathways important in the resolution of ongoing inflammation. A particular interest is the role of oxygen metabolism and concomitant hypoxia associated with inflammatory processes. These studies have unveiled new insight into the inflammatory tissue microenvironment and how such principles might be applied to novel therapies for diseases such as inflammatory bowel disease.

Valina L. Dawson  

Johns Hopkins University, Baltimore

Valina L. Dawson
Valina Dawson studies the cellular signaling involved in neuronal survival and death with a focus on models of Parkinson’s disease and stroke. Her laboratory has explored the role of Parthanatos in neuronal injury, the biologic dysfunction in Parkinson’s disease resulting from disease causing genetic mutations, and the cellular actions of newly discovered proteins that mediate neuronal protection. Recently she has been extending these studies into human neuronal cultures derived from stem cells.

Kai-Uwe Eckardt  

University of Erlangen, Erlangen

Kai-Uwe Eckardt
Kai-Uwe Eckardt´s main research interests are in the (patho)physiological relevance of hypoxia-inducible gene expression and the development and progression of kidney disease. In recent years his group has characterized the expression of HIF transcription factors in the kidney and shown that activation of the HIF system can protect against various forms of renal injury.

Holger Eltzschig 

University of Colorado, Denver

Holger Eltzschig
Holger Eltzschig´s research focuses on the role of hypoxia-elicited adaptive responses in the context of organ failure with particular interest in endogenous adaptive pathways that are under the control of hypoxia-inducible factors. His group has identified novel roles for hypoxia-dependent signaling pathways in the context of several molecular pathways, for example during the extracellular generation and signaling of adenosine. These molecular concepts have been applied in a wide range of disease models that are important for the field of anesthesiology and critical care medicine, including myocardial ischemia, acute kidney injury, liver ischemia or acute lung injury. They are currently exploring translational approaches that might lead to novel treatment strategies for patients requiring major surgery or experiencing critical illness.

Agnes Görlach  

Experimental and Molecular Pediatric Cardiology German Heart Center Munich

Prof. Agnes Görlach
Agnes Görlach’s research focuses on elucidating the physiological and pathophysiological importance of oxygen related pathways. A major research interest relates to the role of reactive oxygen species (ROS) in the control of cardiovascular and pulmonary function and disease as well as in the pathogenesis of tumor and metabolic diseases under normoxic and hypoxic conditions. Her laboratory studies the functional importance of NADPH oxidases, a family of ROS-generating enzymes. Recent research activities extend to the role of oxygen signaling cascades in early life and ageing.

Cynthia Ju  

University of Colorado, Denver

Cynthia Ju’s research focuses on understanding the role of the innate immunity in acute and chronic inflammatory liver diseases, including drug-induced liver injury, alcohol liver disease, and nonalcoholic fatty liver disease. Her laboratory has demonstrated the pathological or protective involvements of neutrophils, macrophages, natural killer (NK) and NK T cells. They currently focus on hepatic macrophages and are investigating the molecular signaling pathways that regulate the phenotypes and functions of these cells. The findings will provide the knowledge basis for developing macrophage-targeted therapeutic strategies to slow down and/or reverse the progression of liver diseases.

Depei Liu  

Chinese Academy of Engineering, Beijing

Depei Liu’s work focuses on gene clusters/families, including genes clusters of Globin, PON, Apo, HOX and gene family of Sirtuins.
He studies regulatory mechanisms for gene expression of these gene clusters at different levels, including histone modification, chromosome conformation, and nuclear localization, and he investigated the physiological / pathophysiological roles of PON, Apo, and Sirtuins gene cluster/family in cardiovascular diseases.

Anthony P. Monaco 

Tufts University, Medford

Anthony P Monaco
Anthony P. Monaco is the current president of Tufts University in Medford, Massachusetts, USA, and a visiting professor at the Wellcome Trust Center for Human Genetics, University of Oxford, Oxford, UK. His research interests focus on the genetic basis of neurodevelopmental disorders including autism, specific language impairment and reading disorders (dyslexia). His group's significant achievements include the identification of a gene (KIAA0319) involved in susceptibility to dyslexia and the identification of Forkhead-Box-Protein P2 (FOXP2), the first gene specifically involved in human speech and language.

Victor Nizet  

UCSD, La Jolla

Victor Nizet
Victor Nizet's research interests are focused in interrelated areas: (1) discovery and characterization of virulence mechanisms of common Gram-positive bacterial pathogens, (2) understanding key aspects of innate immune defense against invasive bacterial infection, and (3) innovative approaches to anti-infective therapy, including neutralizing bacterial virulence factors or boosting innate immune cell function.

Michael Roden  

German Diabetes Center, Düsseldorf

Michael Roden
Michael Roden is scientific director of the German Diabetes Center in Duesseldorf. The mission of the German Diabetes Center (DDZ) is to provide interdisciplinary scientific contributions aimed at reducing the individual and social burden of diabetes. His research interests are focused on diabetes, insulin resistance, energy metabolism, obesity and hypertension.

Jonathan Sleeman 

University of Heidelberg, Medical Faculty Mannheim, Germany

Jonathan Sleeman is Professor of Microvascular Biology and Pathobiology at the University of Heidelberg, Germany (Medical Faculty Mannheim) and is also affiliated with KIT Karlsruhe, Germany.
Dr. Sleeman’s research aims to understand the cellular and molecular regulation of metastasis and to use this knowledge to develop novel anti-cancer therapies. This work currently encompasses studies on (a) genetic changes and signalling pathways that promote metastasis; (b) tumor-induced lymphangiogenesis and dissemination via the lymphatics; (c) the involvement of cancer stem cells and niche structures in metastatic spread and dormancy; (d) changes in extracellular matrix components (in particular hyaluronic acid) and pro-inflammatory signaling molecules as regulators of dissemination and metastatic outgrowth.

Makoto Suematsu  

Keio University, Tokyo

Makoto Suematsu
Makoto Suematsu’s research focuses on Gas Biology and Medicine. He has revealed that carbon monoxide generated in our body serves as a potent regulator of microvascular tone. The fact that gases target metal-centered prosthetic groups of proteins has led him to apply advanced metabolome analysis and imaging MS for exploring gas-responsive macromolecules in biological systems and to investigate their medical implications.

Danny Welch 

Danny Welch
Danny Welch´s research aims at determining the mechanisms by which tumor cells acquire the ability to metastasize. In recent years his group has focused on metastasis suppressors and they have cloned six of them: KISS1, BRMS1, TXNIP, CRSP3 and two microRNA. When metastatic cancer cells are engineered to re-express metastasis suppressors, metastasis is suppressed without blocking tumor formation. The current focus of the lab is to understand the mechanisms by which these molecules block metastasis.

Cornelia Weyand  

Stanford University, Stanford

Cornelia Weyand
Cornelia Weyand´s main research interests are in the role of the immune system in chronic inflammatory disease and the immuno-stromal interactions that shape tissue inflammation. In recent years her laboratory has studied the impact of immune aging on protective and damaging immune responses and has identified deficiencies in the molecular machinery of telomere protection, DNA damage sensing and DNA repair as elements in premature immune aging. Her team has defined tissue-injurious immune effector mechanisms in vascular inflammation with emphasis on vasculitis and atherosclerosis.

Rui-Ping Xiao 

Peking University, Beijing

Rui-Ping Xiao
Rui-Ping Xiao´s main scientific focus has been G-protein coupled receptor (GPCR) signaling in the cardiovascular system. Her work has revealed dual coupling of b2-adrenergic receptor (b2AR) with two functionally opposite G-protein families, Gs and Gi proteins, and its physiological and pathophysiological significance. Ongoing research directions include signaling pathways involved in metabolic disorders and related cardiovascular complications, in particular, mechanisms underlying obesity, type-2 diabetes, atherosclerosis as well as cardiovascular aging and heart failure. Her work aims to develop novel therapies for the treatment of metabolic disorders and resultant cardiovascular complications.

Reviews Editor 

Xuetao Cao  

Chinese Academy of Medical Sciences, Beijing

Xuetao Cao
Xuetao Cao is Professor and President of Chinese Academy of Medical Sciences, Beijing, China. His major interests are innate signaling and immune regulation, immunobiology of APCs (dendritic cells, macrophages), cancer immunotherapy. He has identified important mediators and regulators of innate immune signaling, characterized immune subsets with regulatory function, investigated several approaches to dendritic cell-based immunotherapy of cancer, contributing to the understanding of signaling pathways and cellular effectors in innate immunity, inflammation and tumor immunology.

Ann Chambers  

London Health Sciences Centre, London, Ontario

Ann Chambers
Ann Chambers´ research interests focus on the understanding of metastasis and tumor dormancy using experimental and clinical approaches. She has used in vivo imaging to clarify steps and molecular mechanisms of metastasis. She has discovered that large numbers of dormant single cells may remain in secondary organs, with the potential to resume growth at later times to form metastases. Her research suggests that new anti-metastatic therapies should be directed against growth of cancer cells after they have arrived in the new organ and that new approaches are needed to prevent, delay or treat development of metastatic disease.

Stefan Offermanns 

Max Planck Institute for Heart and Lung Research, Frankfurt

Stefan Offermanns
Stefan Offermanns is director at the Max Planck Institute for Heart and Lung Research and professor of pharmacology at the Goethe University, Frankfurt. His research interests focus on cellular and biological functions of G-protein-mediated signal transduction processes, regulation of cellular functions via plexins, and the characterization of new G-protein-coupled receptors as pharmacological targets. He combines basic science with clinically oriented research to study the role of these receptors and signalling pathways in the cardiovascular and metabolic system as well as in cancer.

For authors and editors

  • Journal Citation Reports®
    2016 Impact Factor
  • 4.686
  • Aims and Scope

    Aims and Scope


    The Journal of Molecular Medicine publishes reports describing major advances in the understanding, prevention, diagnosis, or treatment of human disease through the application of molecular biology and gene technology, a research discipline that has become known as molecular medicine.

    The journal publishes original papers and review articles of the highest quality pertinent to all aspects of human biology and pathophysiology. Covered areas include, but are not limited to:
    aging, angiogenesis, cancer biology and oncology, development and differentiation, endocrinology and metabolic disorders, gastrointestinal diseases and hepatology, genetics and epigenetics, hematology, hypoxia research, immunology, infectious diseases, neuroscience of diseases, -omics based research of diseases, systems medicine, regenerative medicine, stem cell research, vascular and cardiovascular biology.

    Good reasons for publishing your best paper in J Mol Med:

    • High impact: 4.768 (2012 IF)
    • Wide distribution: More than 8,100 institutions worldwide having full text access
    • Wide readership: Almost 29,000 full text downloads per month
    • Rapid editorial handling: 17 days from submission to first decision
    • Rapid publication: 19 days from acceptance to online publication
    • Commitment to fairness: Author feedback program
    • No page charges, no submission charges

     J Mol Med is the continuation of the Berliner Klinische Wochenschrift (1864), one of the oldest and most prestigious European journals in which great scientists such as Paul Ehrlich, Robert Koch and Otto Warburg published their seminal, epoch-making discoveries.

  • Submit Online
  • Open Choice - Your Way to Open Access
  • Instructions for Authors

    Instructions for Authors


  • Everything an Author Needs

    Everything an Author Needs


  • Author Academy: Training for Authors
  • Copyright Information

    Copyright Information


    Copyright Information

    For Authors

    Submission of a manuscript implies: that the work described has not been published before (except in form of an abstract or as part of a published lecture, review or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all co-authors, if any, as well as – tacitly or explicitly – by the responsible authorities at the institution where the work was carried out.

    Author warrants (i) that he/she is the sole owner or has been authorized by any additional copyright owner to assign the right, (ii) that the article does not infringe any third party rights and no license from or payments to a third party is required to publish the article and (iii) that the article has not been previously published or licensed. The author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors. Transfer of copyright to Springer (respective to owner if other than Springer) becomes effective if and when a Copyright Transfer Statement is signed or transferred electronically by the corresponding author. After submission of the Copyright Transfer Statement signed by the corresponding author, changes of authorship or in the order of the authors listed will not be accepted by Springer.

    The copyright to this article, including any graphic elements therein (e.g. illustrations, charts, moving images), is assigned for good and valuable consideration to Springer effective if and when the article is accepted for publication and to the extent assignable if assignability is restricted for by applicable law or regulations (e.g. for U.S. government or crown employees).

    The copyright assignment includes without limitation the exclusive, assignable and sublicensable right, unlimited in time and territory, to reproduce, publish, distribute, transmit, make available and store the article, including abstracts thereof, in all forms of media of expression now known or developed in the future, including pre- and reprints, translations, photographic reproductions and microform. Springer may use the article in whole or in part in electronic form, such as use in databases or data networks for display, print or download to stationary or portable devices. This includes interactive and multimedia use and the right to alter the article to the extent necessary for such use.

    Authors may self-archive the Author's accepted manuscript of their articles on their own websites. Authors may also deposit this version of the article in any repository, provided it is only made publicly available 12 months after official publication or later. He/she may not use the publisher's version (the final article), which is posted on SpringerLink and other Springer websites, for the purpose of self-archiving or deposit. Furthermore, the Author may only post his/her version provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".

    Prior versions of the article published on non-commercial pre-print servers like arXiv.org can remain on these servers and/or can be updated with Author's accepted version. The final published version (in pdf or html/xml format) cannot be used for this purpose. Acknowledgement needs to be given to the final publication and a link must be inserted to the published article on Springer's website, accompanied by the text "The final publication is available at link.springer.com". Author retains the right to use his/her article for his/her further scientific career by including the final published journal article in other publications such as dissertations and postdoctoral qualifications provided acknowledgement is given to the original source of publication.

    Author is requested to use the appropriate DOI for the article. Articles disseminated via link.springer.com are indexed, abstracted and referenced by many abstracting and information services, bibliographic networks, subscription agencies, library networks, and consortia.

    For Readers

    While the advice and information in this journal is believed to be true and accurate at the date of its publication, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may have been made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

    All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher (respective the copyright owner if other than Springer). The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

    Springer has partnered with Copyright Clearance Center's RightsLink service to offer a variety of options for reusing Springer content. For permission to reuse our content please locate the material that you wish to use on link.springer.com or on springerimages.com and click on the permissions link or go to copyright.com, then enter the title of the publication that you wish to use. For assistance in placing a permission request, Copyright Clearance Center can be connected directly via phone: +1-855-239-3415, fax: +1-978-646-8600, or e-mail: info@copyright.com.

    © Springer-Verlag Berlin Heidelberg

Services for the Journal

Alerts for this journal


Get the table of contents of every new issue published in Journal of Molecular Medicine.